HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal

  • RnM3875473
  • |
  • 05 February, 2020
  • |
  • 63 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Check Discount on this report



Purchase this Report

$6,995.00
$13,990.00
$20,985.00
5,575.02
11,150.03
16,725.05
6,498.36
12,996.71
19,495.07
1,071,843.85
2,143,687.70
3,215,531.55
583,662.80
1,167,325.60
1,750,988.40
Credit card Logo